Technology
HEAG Launches Innovative AI Tool to Assist Financial Aid Professionals
Published
2 years agoon
By
Designed for HEAG’s consulting staff, ReggieAI will provide quick, accurate, and detailed answers to specific Title IV Financial Aid processing questions that will streamline the Title IV compliance process and significantly benefit our college and university clients.
WELLESLEY, Mass., Dec. 16, 2024 /PRNewswire-PRWeb/ — The Higher Education Assistance Group (HEAG), a leader in Title IV Financial Aid consulting and outsourcing, is thrilled to announce the launch of its groundbreaking new AI tool, ReggieAI. Designed for our consulting staff, ReggieAI will provide quick, accurate, and detailed answers to specific Title IV Financial Aid processing questions that will streamline the Title IV compliance process and significantly benefit our college and university clients.
This robust, cutting-edge technology promises to save HEAG consultants valuable time in finding the answers to complex Title IV regulatory questions. ReggieAI leverages advanced artificial intelligence to search industry specific information, including regulatory policies and procedures, student eligibility requirements, and federal loan processing questions. With its innovative capabilities, the tool is set to redefine the Title IV Financial Aid consulting industry.
“Navigating the various available resources to obtain answers to Title IV regulatory and compliance questions is time consuming and can cause delays for students who need to secure federal funds to attend college,” said Milton Kerstein, President of the Higher Education Assistance Group. “Our AI Chatbot, Reggie AI, provides our consultants with instantaneous answers to difficult questions, significantly reducing the time it takes to respond to student inquiries or handle a processing request, thereby streamlining the Title IV process and improving the overall financial aid experience for students and families.”
About HEAG
The launch of ReggieAI aligns with HEAG’s commitment to quality, service and compliance.
Located just outside Boston, Massachusetts, HEAG is the premier Title IV Student Financial Aid compliance and technology consulting firm. We provide holistic solutions that help colleges optimize technology and business processes so they can successfully support their students.
We specialize in compliance with Title IV rules and regulations and have successfully provided operational guidance and support to the higher education community for well over 30 years. We pride ourselves on compliance expertise and our ability to adapt to an ever-changing industry. By staying abreast of regulatory changes and new technology solutions, HEAG is a consistent resource for public and private institutions of all sizes and types across the country.
Learn more about the launch of ReggieAI by contacting HEAG’s Vice President of Compliance & Quality Assurance at kwrightmoore@heag.us.
Request or inquire about HEAG services at info@heag.us.
Visit us at www.heag.us.
Media Contact
Melissa Maichle, Higher Education Assistance Group, 1 7815348620, melmaichle@gmail.com, https://heag.us/
View original content to download multimedia:https://www.prweb.com/releases/heag-launches-innovative-ai-tool-to-assist-financial-aid-professionals-302331947.html
SOURCE Higher Education Assistance Group
You may like
Q3 revenue of $325.6M, up 21% year over year
Q3 net income of $31.0M and non-GAAP net income of $87.1M
Q3 net income margin of 10%; adjusted EBITDA margin of 43%
LEHI, Utah and LOUISVILLE, Ky., Nov. 2, 2026 /PRNewswire/ — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the third quarter ended September 30, 2026.
“Waystar delivered another quarter of robust bookings and healthy demand across the business,” said Matt Hawkins, Chief Executive Officer of Waystar. “Providers are increasingly consolidating more of the revenue cycle onto Waystar’s connected platform, deepening relationships across both new and existing clients as they adopt more of our AI-powered capabilities. We are focused on executing against the opportunities in front of us and extending our market leadership as we leverage AI and agentic capabilities to reshape the revenue cycle.”
Third Quarter 2026 Financial Highlights
Revenue of $325.6 million, up 21% year-over-yearNet income of $31.0 million, GAAP net income per diluted share of $0.16, and net income margin of 10%Non-GAAP net income of $87.1 million and non-GAAP net income per diluted share of $0.44Adjusted EBITDA of $139.3 million and adjusted EBITDA margin of 43%Cash flow from operations of $103.9 million and unlevered free cash flow of $114.8 million
Key Performance Metrics and Revenue Disaggregation
1,488 clients contributed over $100,000 in LTM revenue, up 14% year-over-yearNet revenue retention rate (NRR) of 108%Third quarter 2026 subscription revenue of $180.7 million, up 34% year-over-yearThird quarter 2026 volume-based revenue of $142.9 million, up 8% year-over-yearThird quarter 2026 provider revenue of $243.4 million, up 28% year-over-yearThird quarter 2026 patient revenue of $82.2 million, up 5% year-over-year
Financial Outlook
As of November 2, 2026, Waystar provides the following guidance for its full fiscal year 2026.1
Total revenue is expected to be between $1.277 billion and $1.287 billionAdjusted EBITDA is expected to be between $543 million and $549 millionNon-GAAP net income is expected to be between $322 million and $337 millionDiluted non-GAAP net income per share is expected to be between $1.63 and $1.71
Webcast Information
Waystar will discuss its financial results on a conference call scheduled at 4:30 p.m. Eastern Time today, November 2, 2026. A live audio conference call will be available on Waystar’s website at https://investors.waystar.com/news-events/events. Waystar will archive the webcast on its site for those unable to listen in real time. This earnings release and the related Current Report on Form 8-K, furnished November 2, 2026, are available on the Investor Relations page of Waystar’s website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, U.S. Securities and Exchange Commission (“SEC”) filings, and public conference calls and webcasts.
Non-GAAP Financial Measures
To supplement the consolidated financial statements prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release contains certain non-GAAP financial measures as defined below. We present non-GAAP financial measures as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. We believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate, and capital investments. Management uses adjusted EBITDA and adjusted EBITDA margin to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures. Management uses non-GAAP net income and non-GAAP net income per share to evaluate our core operating profitability on an after-tax basis exclusive of certain non-cash and non-recurring items that Management does not believe are indicative of our core operating performance, and to facilitate comparison with peer companies that may have different capital structures, acquisition histories, or tax profiles. Management uses non-GAAP operating expenses to evaluate trends in our cost structure excluding the items above. Management uses unlevered free cash flow to evaluate cash generation from our core business operations independent of our capital structure. Management uses net debt, gross debt, adjusted net leverage ratio and adjusted gross leverage ratio to evaluate our capital structure and leverage. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide.
Adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income, non-GAAP net income per share, non-GAAP operating expenses, unlevered free cash flow, net debt, gross debt, adjusted net leverage ratio and adjusted gross leverage ratio are not recognized terms under GAAP and should not be considered as an alternative to net income (loss), net income (loss) margin or the related GAAP expense line items as measures of financial performance, cash provided by operating activities as a measure of liquidity, total debt as a measure of indebtedness, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use, as they do not consider certain cash requirements such as interest payments, tax payments, and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. A reconciliation is provided below for our non-GAAP financial measures to the most directly comparable financial measure stated in accordance with GAAP. A quantitative reconciliation of the forward-looking non-GAAP financial measures included in our financial outlook is not provided for the reasons described under “Financial Outlook.” Investors are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
The following non-GAAP financial measures and key performance metrics are defined below:
Adjusted EBITDA and adjusted EBITDA Margin
We define adjusted EBITDA as net income / (loss) before interest expense, net, income tax expense / (benefit), depreciation and amortization, and as further adjusted for stock-based compensation expense, acquisition, integration and transaction costs, asset and lease impairments, costs related to amended debt agreements, IPO and secondary offering costs and costs related to other unusual, non-recurring or otherwise notable items. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
Non-GAAP Net Income and Non-GAAP Net Income Per Share
We define non-GAAP net income as GAAP net income excluding the impact of stock-based compensation, acquisition, integration and transaction costs, asset and lease impairments, costs related to our IPO, and the Secondary Offerings, costs related to amended debt agreements and amortization of intangibles, and costs related to other unusual, non-recurring or otherwise notable items. The tax effects of the adjustments are calculated using a management estimated annual effective non-GAAP tax rate of 21%, which is based on our statutory federal tax rate and provides consistency across interim reporting periods by eliminating the effects of non-recurring and period-specific items. Due to the differences in the tax treatment of items excluded from non-GAAP net income, our estimated tax rate on non-GAAP net income may differ from our GAAP tax rate. Non-GAAP net income per share is shown on both a basic and diluted basis and is defined as non-GAAP net income divided by the basic or diluted weighted-average shares, respectively.
Unlevered Free Cash Flow
We define unlevered free cash flow as cash from operations plus cash interest paid less capital expenses.
Net Debt
We define net debt as the sum of the current portion of long-term debt, long-term debt, and accounts receivable securitization less cash and equivalents and investment securities.
Adjusted Net Leverage Ratio
We define adjusted net leverage ratio as net debt divided by adjusted EBITDA over the preceding twelve months.
Gross Debt
We define gross debt as the sum of the current portion of long-term debt, long-term debt, and accounts receivable securitization.
Adjusted Gross Leverage Ratio
We define adjusted gross leverage ratio as gross debt divided by adjusted EBITDA over the preceding twelve months.
Key Performance Metrics
Net Revenue Retention Rate
Our Net Revenue Retention Rate compares twelve months of client invoices for our solutions at two period end dates. To calculate our Net Revenue Retention Rate, we first accumulate the total amount invoiced during the twelve months ending with the prior period-end or Prior Period Invoices. We then calculate the total amount invoiced to those same clients for the twelve months ending with the current period-end, or Current Period Invoices. Current Period Invoices are inclusive of upsell, downsell, pricing changes, clients that cancel or chose not to renew, and discontinued solutions with continuing clients. The Net Revenue Retention Rate is then calculated by dividing the Current Period Invoices by the Prior Period Invoices. Our total invoices included in the analysis are greater than 98% of reported revenue. We use Net Revenue Retention Rate to evaluate our ongoing operations and for internal planning and forecasting purposes. Acquired businesses are included in the last-twelve-month Net Revenue Retention Rate in the ninth quarter after acquisition, which is the earliest point that comparable post-acquisition invoices are available for both the current and prior twelve-month period.
Customer Count with >$100,000 of Revenue
We regularly monitor and review our count of clients who generate more than $100,000 of revenue.
Our count of clients who generate more than $100,000 of revenue is based on an accumulation of the amounts invoiced to clients over the preceding twelve months. The invoices for acquired clients are included starting in the first full calendar quarter after the date of acquisition.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, statements regarding Waystar’s expectations relating to future operating results and financial position, including full year 2026, and future periods; the performance of our new product offerings; our industry and market opportunities, business strategy, goals, and expectations concerning our market position, future operations, margins and profitability, capital expenditures, liquidity, and capital resources and other financial and operating information. Forward-looking statements include all statements that are not historical facts. These statements may include words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” “outlook,” the negative version of these words or similar terms and phrases to identify forward-looking statements in this press release, including the discussion of outlook for full fiscal year 2026.
The forward-looking statements contained in this press release are based on management’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. The following factors are among those that may cause actual results to differ materially from the forward-looking statements: our operation in a highly competitive industry; our ability to retain our existing clients and attract new clients; our ability to successfully execute on our business strategies in order to grow; our ability to accurately assess the risks related to acquisitions and successfully integrate acquired businesses, including the acquisition of Iodine; our ability to establish and maintain strategic relationships; the growth and success of our clients and overall healthcare transaction volumes; consolidation in the healthcare industry; our selling cycle of variable length to secure new client agreements; our implementation cycle that is dependent on our clients’ timing and resources; our dependence on our senior management team and certain key employees, and our ability to attract and retain highly skilled employees; the accuracy of the estimates and assumptions we use to determine the size of our total addressable market; our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes or evolving industry standards; the interoperability, connectivity, and integration of our solutions with our clients’ and their vendors’ networks and infrastructures; the performance and reliability of internet, mobile, and other infrastructure; the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions; our reliance on certain third-party vendors and providers; any errors or malfunctions in our products and solutions; failure by our clients to obtain proper permissions or provide us with accurate and appropriate information; the potential for embezzlement, identity theft, or other similar illegal behavior by our employees or vendors, and a failure of our employees or vendors to observe quality standards or adhere to environmental, social, and governance standards; our compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks; increases in card network fees and other changes to fee arrangements; the effect of payer and provider conduct which we cannot control; privacy concerns and security breaches or incidents relating to our platform or data (including personal information and other regulated data); the complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity; our ability to adequately protect and enforce our intellectual property rights; our ability to use or license data and integrate third-party technologies; the development, deployment, and use of AI; our use of “open source” software; legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights; claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties; the heavily regulated industry in which we conduct business; the uncertain and evolving healthcare regulatory and political framework; healthcare laws and data privacy and security laws and regulations governing our Processing of personal information (which may also be referred to as “personal data” or “personally identifiable information”); reduced revenues in response to changes to the healthcare regulatory landscape; legal, regulatory, and other proceedings that could result in adverse outcomes; contractual obligations requiring compliance with certain provisions of the Bank Secrecy Act/anti-money laundering laws and regulations; existing laws that regulate our ability to engage in certain marketing activities; our full compliance with website accessibility standards; any changes in our tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities; limitations on our ability to use our net operating losses to offset future taxable income; losses due to asset impairment charges; our substantial debt and restrictive covenants in the agreements governing our Credit Facilities; interest rate fluctuations; unavailability of additional capital on acceptable terms or at all; the impact of general macroeconomic conditions; our history of net losses and our ability to achieve or maintain profitability; the interests of certain investors may be different than the interests of other holders of our securities; and each of the other factors discussed under the heading of “Risk Factors” in the Company’s 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2026, and in other reports filed with the SEC, all of which are available on the Investor Relations page of our website at investors.waystar.com.
Any forward-looking statements made by us in this press release speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.
About Waystar
Waystar’s mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing approximately 1.5 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar’s enterprise-grade platform annually processes over 8.5 billion healthcare payment transactions, including over $3.0 trillion in annual gross claims and spanning approximately 60% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
1We have not reconciled the forward-looking adjusted EBITDA, non-GAAP net income, and non-GAAP net income per share guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, and certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
Waystar Holding Corp.
Unaudited Consolidated Statements of Operations
(in thousands, except for share and per share data)
Three months ended
September 30,
Nine months ended
September 30,
2026
2025
2026
2025
Revenue
$ 325,624
$ 268,651
$ 959,172
$ 795,740
Operating expenses
Cost of revenue (exclusive of
depreciation and amortization expenses)
99,202
85,136
293,923
255,525
Sales and marketing
51,998
45,158
148,207
128,805
General and administrative
51,393
32,422
118,495
84,914
Research and development
20,299
12,403
56,390
36,103
Depreciation and amortization
41,466
33,300
124,384
100,106
Total operating expenses
264,358
208,419
741,399
605,453
Income from operations
61,266
60,232
217,773
190,287
Other expense
Interest expense, net
(18,182)
(16,613)
(56,531)
(52,195)
Related party interest expense
(1,115)
(902)
(3,059)
(2,475)
Income before income taxes
41,969
42,717
158,183
135,617
Income tax expense
10,944
12,069
43,008
43,516
Net income
$ 31,025
$ 30,648
$ 115,175
$ 92,101
Net income per share:
Basic
0.16
0.18
0.60
0.53
Diluted
0.16
0.17
0.59
0.51
Weighted-average shares outstanding:
Basic
191,938,402
174,352,079
191,825,646
173,388,077
Diluted
195,913,142
181,240,033
195,743,104
181,165,738
Waystar Holding Corp.
Unaudited Consolidated Balance Sheets
(in thousands, except for share and per share data)
September 30,
2026
December 31,
2025
Assets
Current assets
Cash and cash equivalents
$ 30,820
$ 61,355
Restricted cash
24,161
15,454
Investment securities
246,075
24,877
Accounts receivable, net of allowance of $4,130 at
September 30, 2026 and $6,170 at December 31, 2025
187,007
177,037
Income tax receivable
—
6,437
Prepaid expenses
22,834
20,078
Other current assets
4,551
3,174
Total current assets
515,448
308,412
Property, plant and equipment, net
73,172
51,649
Operating lease right-of-use assets, net
11,922
12,972
Intangible assets, net
1,189,418
1,292,839
Goodwill
4,014,868
4,016,818
Deferred costs
110,720
93,951
Other long-term assets
7,292
8,459
Total assets
$ 5,922,840
$ 5,785,100
Liabilities and stockholders’ equity
Current liabilities
Accounts payable
$ 68,078
$ 50,949
Accrued compensation
31,025
40,942
Aggregated funds payable
23,369
15,104
Other accrued expenses
38,020
22,990
Deferred revenue
64,773
67,855
Current portion of long-term debt
13,404
13,537
Related party current portion of long-term debt
790
657
Current portion of operating lease liabilities
5,713
6,029
Total current liabilities
245,172
218,063
Long-term liabilities
Deferred tax liability
174,539
211,320
Long-term debt, net, less current portion
1,374,057
1,394,523
Related party long-term debt, net, less current portion
75,468
64,186
Operating lease liabilities, net of current portion
11,163
11,994
Deferred revenue – long-term
5,572
5,496
Other long-term liabilities
278
692
Total liabilities
1,886,249
1,906,274
Commitments and contingencies (Note 20)
Stockholders’ equity
Preferred stock $0.01 par value – 100,000,000 shares authorized as of September 30, 2026
and December 31, 2025, respectively; zero shares issued or outstanding as of
September 30, 2026 and December 31, 2025, respectively
—
—
Common stock $0.01 par value – 2,500,000,000 shares authorized at September 30, 2026
and December 31, 2025, respectively; 193,813,805 and 191,587,193 shares outstanding at
September 30, 2026 and December 31, 2025, respectively; 192,265,522 and 191,587,193
shares outstanding at September 30, 2026 and December 31, 2025, respectively
1,938
1,916
Treasury stock, at cost
(33,487)
—
Additional paid-in capital
4,060,817
3,986,353
Accumulated other comprehensive income (loss)
959
(632)
Retained earnings (accumulated deficit)
6,364
(108,811)
Total stockholders’ equity
4,036,591
3,878,826
Total liabilities and stockholders’ equity
$ 5,922,840
$ 5,785,100
Waystar
Unaudited Consolidated Statements of Cash Flows
(in thousands)
Nine Months Ended September 30,
2026
2025
Cash flows from operating activities
Net income
$ 115,175
$ 92,101
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization
124,384
100,106
Stock-based compensation
49,691
29,871
Provision for bad debt expense
2,884
2,605
Loss on extinguishment of debt
113
711
Impairment expense
1,990
—
Deferred income taxes
(37,490)
22,959
Amortization of debt discount and issuance costs
2,010
2,021
Other
86
—
Changes in:
Accounts receivable
(12,854)
(3,045)
Income tax receivable
6,437
2,838
Prepaid expenses and other current assets
(4,898)
(4,980)
Deferred costs
(16,282)
(7,116)
Other long-term assets
705
(2,362)
Accounts payable and accrued expenses
20,824
10,580
Deferred revenue
(3,006)
(1,863)
Operating lease right-of-use assets and lease liabilities
(1,582)
(1,387)
Net cash provided by operating activities
248,187
243,039
Cash flows from investing activities
Purchase of property and equipment and capitalization of internally developed software costs
(41,359)
(17,069)
Purchase of investment securities
(368,341)
(206,444)
Proceeds from sale or maturity of investment securities
149,088
206,444
Measurement period adjustments related to prior year acquisition
2,037
—
Net cash used in investing activities
(258,575)
(17,069)
Cash flows from financing activities
Change in aggregated funds liability
8,265
1,789
Repurchase of common stock
(33,487)
—
Proceeds from issuance of common stock from employee equity plans
24,628
22,439
Proceeds from issuances of debt, net of creditor fees
19,800
—
Payments on debt
(30,646)
(8,751)
Finance lease liabilities paid
—
(672)
Net cash provided by (used in) financing activities
(11,440)
14,805
Increase/(decrease) in cash and cash equivalents during the period
(21,828)
240,775
Cash and cash equivalents and restricted cash–beginning of period
76,809
204,582
Cash and cash equivalents and restricted cash–end of period
$ 54,981
$ 445,357
Supplemental disclosures of cash flow information
Interest paid
$ 62,124
$ 59,303
Cash taxes paid (refunds received), net
58,882
9,439
Non-cash investing and financing activities
Fixed asset purchases in accounts payable
996
539
Reconciliation of Balance Sheet Cash Accounts to Cash Flow Statement
Balance sheet
Cash and cash equivalents
30,820
421,056
Restricted cash
24,161
24,301
Total
54,981
445,357
Waystar
Reconciliation of Adjusted EBITDA
(in thousands)
(unaudited)
Three months ended
September 30,
Nine months ended
September 30,
($ in thousands)
2026
2025
2026
2025
Net income
$ 31,025
$ 30,648
$ 115,175
$ 92,101
Interest expense, net
19,297
17,515
59,590
54,670
Income tax expense
10,944
12,069
43,008
43,516
Depreciation and amortization
41,466
33,300
124,384
100,106
Stock-based compensation expense
24,442
11,597
49,691
29,871
Acquisition, integration and transaction costs
9,629
5,313
13,236
6,197
Asset and lease impairments
—
—
1,990
—
Other (a)
2,499
2,261
4,356
6,540
Adjusted EBITDA
$ 139,302
$ 112,703
$ 411,430
$ 333,001
Revenue
$ 325,624
$ 268,651
$ 959,172
$ 795,740
Net income margin
9.5 %
11.4 %
12.0 %
11.6 %
Adjusted EBITDA margin
42.8 %
42.0 %
42.9 %
41.8 %
(a)
For the three and nine months ended September 30, 2026, adjustments reflect costs associated with a cybersecurity incident (see Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026) totaling $1.4 million and $3.0 million, respectively and executive severance totaling $1.1 million and $1.1 million, respectively. For the three and nine months ended September 30, 2025, adjustments include secondary offering costs of $1.4 million and $4.6 million, respectively; costs related to amended debt agreements totaling $0.6 million; lease-related costs associated with the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance costs totaling $0.0 million and $0.6 million, respectively.
Waystar
Reconciliation of Non-GAAP Operating Expenses
(in thousands)
(unaudited)
Three months ended
September 30,
Nine months ended
September 30,
2026
2025
2026
2025
Cost of revenue (exclusive of depreciation and amortization expenses)
$ 99,202
$ 85,136
$ 293,923
$ 255,525
Less Stock-based compensation expense
(1,072)
(418)
(2,101)
(1,064)
Less Acquisition, integration and transaction costs
(1,011)
(3)
(3,266)
(3)
Less Other (a)
(2)
–
(2)
–
Cost of revenue (exclusive of depreciation and amortization expenses), adjusted
$ 97,117
$ 84,715
$ 288,554
$ 254,458
Sales and marketing
51,998
45,158
148,207
128,805
Add/(Less) Stock-based compensation expense
(2,520)
(2,392)
(4,867)
(6,198)
Add/(Less) Acquisition, integration and transaction costs
–
(79)
54
(79)
Less Other (a)
(146)
–
(246)
–
Sales and marketing, adjusted
$ 49,332
$ 42,687
$ 143,148
$ 122,528
General and administrative
51,393
32,422
118,495
84,914
Less Stock-based compensation expense
(18,182)
(7,218)
(36,499)
(18,418)
Less Acquisition, integration and transaction costs
(7,681)
(5,119)
(8,878)
(5,778)
Less Asset and lease impairments
–
–
(1,990)
–
Less Other (a)
(2,347)
(2,261)
(4,104)
(6,540)
General and administrative, adjusted
$ 23,183
$ 17,824
$ 67,024
$ 54,178
Research and development
20,299
12,403
56,390
36,103
Less Stock-based compensation expense
(2,668)
(1,569)
(6,224)
(4,191)
Less Acquisition, integration and transaction costs
(937)
(112)
(1,146)
(337)
Less Other (a)
(4)
–
(4)
–
Research and development, adjusted
$ 16,690
$ 10,722
$ 49,016
$ 31,575
Depreciation and amortization
41,466
33,300
124,384
100,106
Less Intangible amortization
(34,474)
(27,851)
(103,421)
(84,081)
Depreciation and amortization, adjusted
$ 6,992
$ 5,449
$ 20,963
$ 16,025
Income tax expense
10,944
12,069
43,008
43,516
Plus Tax effect of adjustments
14,919
9,875
36,266
26,605
Income tax expense, adjusted
$ 25,863
$ 21,944
$ 79,274
$ 70,121
(a)
For the three and nine months ended September 30, 2026, adjustments reflect costs associated with a cybersecurity incident (see Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026) totaling $1.4 million and $3.0 million, respectively, and executive severance totaling $1.1 million and $1.1 million, respectively. For the three and nine months ended September 30, 2025, adjustments include secondary offering costs of $1.4 million and $4.6 million, respectively; costs related to amended debt agreements totaling $0.6 million; lease-related costs associated with the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance costs totaling $0.0 million and $0.6 million, respectively.
Waystar
Reconciliation of Non-GAAP Net Income
(in thousands, except share and per share amounts)
(unaudited)
Three months ended
September 30,
Nine months ended
September 30,
($ in thousands)
2026
2025
2026
2025
Net income
$ 31,025
$ 30,648
$ 115,175
$ 92,101
Stock-based compensation
24,442
11,597
49,691
29,871
Acquisition, integration and transaction costs
9,629
5,313
13,236
6,197
Asset and lease impairments
—
—
1,990
—
Other (a)
2,499
2,261
4,356
6,540
Intangible amortization
34,474
27,851
103,421
84,081
Tax effect of adjustments
(14,919)
(9,875)
(36,266)
(26,605)
Non-GAAP net income
$ 87,150
$ 67,795
$ 251,603
$ 192,185
Non-GAAP net income per share:
Basic
$ 0.45
$ 0.39
$ 1.31
$ 1.11
Diluted
$ 0.44
$ 0.37
$ 1.29
$ 1.06
Weighted-average shares outstanding:
Basic
191,938,402
174,352,079
191,825,646
173,388,077
Diluted
195,913,142
181,240,033
195,743,104
181,165,738
(a)
For the three and nine months ended September 30, 2026, adjustments reflect costs associated with a cybersecurity incident (see Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026) totaling $1.4 million and $3.0 million, respectively, and executive severance totaling $1.1 million and $1.1 million, respectively. For the three and nine months ended September 30, 2025, adjustments include secondary offering costs of $1.4 million and $4.6 million, respectively; costs related to amended debt agreements totaling $0.6 million; lease-related costs associated with the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance costs totaling $0.0 million and $0.6 million, respectively.
Waystar
Reconciliation of Unlevered Free Cash Flow
(in thousands)
(unaudited)
Three months ended
September 30,
Nine months ended
September 30,
2026
2025
2026
2025
Net cash provided by operating activities
$ 103,863
$ 82,030
$ 248,187
$ 243,039
Interest paid
20,834
19,558
62,124
59,303
Purchase of PP&E and capitalization of internally developed software costs
(9,919)
(5,876)
(41,359)
(17,069)
Unlevered free cash flow
$ 114,778
$ 95,712
$ 268,952
$ 285,273
Waystar
Reconciliation of Net Debt
(in thousands)
(unaudited)
September 30,
2026
2025
First lien term loan facility outstanding debt, current
$ 14,194
$ 11,668
First lien term loan facility outstanding debt, net of current portion
1,356,407
1,143,127
Receivables facility outstanding debt
100,000
80,000
Cash and cash equivalents
(30,820)
(421,056)
Investment securities
(246,075)
–
Net debt
$ 1,193,706
$ 813,739
Trailing Twelve Months Adjusted EBITDA
$ 540,575
$ 433,154
Adjusted gross leverage ratio
2.7x
2.9x
Adjusted net leverage ratio
2.2x
1.9x
Waystar
Reconciliation of Trailing Twelve Months (TTM) Adjusted EBITDA
(in thousands)
(unaudited)
Three Months Ended
TTM
September 30,
2026
June 30,
2026
March 31,
2026
December 31,
2025
September 30,
2026
Net income
$ 31,025
$ 40,867
$ 43,283
$ 19,988
$ 135,163
Interest expense, net
19,297
19,646
20,647
22,872
82,462
Income tax expense
10,944
15,529
16,535
16,158
59,166
Depreciation and amortization
41,466
41,466
41,452
40,442
164,826
Stock-based compensation expense
24,442
13,803
11,446
12,198
61,889
Acquisition, integration and transaction costs
9,629
1,801
1,806
14,877
28,113
Asset and lease impairments
–
1,990
–
–
1,990
Other (a)
2,499
1,623
234
2,610
6,966
Adjusted EBITDA
$ 139,302
$ 136,725
$ 135,403
$ 129,145
$ 540,575
(a) Adjustments reflect costs associated with a cybersecurity incident (see Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026), costs related to amended debt agreements, secondary offering expenses, executive severance and lease-related costs associated with the relocation of our Louisville office.
Media Contact
Kristin Lee
kristin.lee@waystar.com
Investor Contact
Edward Parker
investors@waystar.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/waystar-reports-third-quarter-2026-results-302926866.html
SOURCE Waystar
Technology
RADIANT LOGISTICS TO HOST INVESTOR CALL TO DISCUSS FINANCIAL RESULTS FOR FIRST FISCAL QUARTER ENDED SEPTEMBER 30, 2026
Published
4 seconds agoon
November 2, 2026By
Call Scheduled for Monday, November 9, at 4:30 PM Eastern
RENTON, Wash., Nov. 2, 2026 /PRNewswire/ — Radiant Logistics, Inc. (NYSE American: RLGT), a technology-enabled global transportation and value-added logistics services company, will host a conference call on Monday, November 9, 2026 at 4:30 PM Eastern to discuss the Company’s financial results for the three months ended September 30, 2026.
The conference call is open to all interested parties, including individual investors and press. Bohn Crain, Founder and CEO will host the call.
Conference Call Details
Date/Time: Monday, November 9, 2026 at 4:30 PM Eastern
DIAL-IN: US (888) 506-0062; Intl. (973) 528-0011
Participant Access Code: 278998
REPLAY: November 10, 2026 at 9:30 AM Eastern to November 23, 2026 at 4:30 PM Eastern
US (877) 481-4010; Intl. (919) 882-2331
Replay ID number: 54749
Webcast Details
This call is also being webcast and may be accessed via Radiant’s web site at www.radiantdelivers.com or at https://www.webcaster5.com/Webcast/Page/2191/54749.
About Radiant Logistics (NYSE American: RLGT)
Radiant Logistics, Inc. (www.radiantdelivers.com) operates as a third-party logistics company, providing technology-enabled global transportation and value-added logistics services primarily to customers in the United States and Canada. Through its comprehensive service officering, Radiant provides domestic and international freight forwarding along with truck and rail brokerage services to a diversified account base including manufactures, distributors and retailers, which it supports from an extensive network of company and agent-owned offices throughout North America and other key markets around the world. Radiant’s value-added logistics services include warehouse and distribution, customs brokerage, order fulfillment, inventory management and technology services.
View original content to download multimedia:https://www.prnewswire.com/news-releases/radiant-logistics-to-host-investor-call-to-discuss-financial-results-for-first-fiscal-quarter-ended-september-30-2026-302926855.html
SOURCE Radiant Logistics, Inc.
Technology
ADC Therapeutics Announces New Employee Inducement Grant
Published
6 seconds agoon
November 2, 2026By
LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company’s common shares to a new employee on November 2, 2026. (“Grant”).
The Grant was offered as material inducement to the employee’s employment. The Grant was approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grant was made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.
The Company is issuing this press release pursuant to Rule 303A.08. The Grant shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).
ADC Therapeutics’ CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.
Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether Tanabe’s marketing authorization application filed with Japan’s Ministry of Health for ZYNLONTA will be accepted, the timing and potential approval of the marketing authorization application for ZYNLONTA in Japan, the timing and payment of future regulatory and commercial milestones related to Japan, Nippon Shinyaku ability to successfully commercialize ZYNLONTA in Japan and the amount of future revenue in Japan and related payments to ADCT; the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; our ability to identify and execute on potential regulatory and compendia pathways; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA including our ability to adequately address the serious concerns related to the LOTIS-5 trial results raised by the FDA at the recent pre-sBLA submission meeting; the timing, submission and outcome of an sBLA related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions and into earlier lines of therapy; whether future LOTIS-7 results will be consistent with or different from the prior disclosure, the timing, results and publication of the full LOTIS-7 trial data and potential compendia inclusion; future regulatory strategy for a Phase 3 trial for the combination of ZYNLONTA plus glofitamab; our expected revenue growth in 2027 and the Company’s ability to sustain or grow ZYNLONTA® revenue in the future; our expected cash runway into 2029; changes in our regulatory and commercial strategy; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain or maintain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities; uncertainties related to a potential change in domicile from Switzerland to Delaware, including the outcome of tax analyses associated with such redomiciliation, the receipt of requisite shareholder approval, and the ability to complete the redomiciliation on the anticipated terms and timeline, if at all; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.
CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-new-employee-inducement-grant-302925153.html
SOURCE ADC Therapeutics SA
Waystar Reports Third Quarter 2026 Results
RADIANT LOGISTICS TO HOST INVESTOR CALL TO DISCUSS FINANCIAL RESULTS FOR FIRST FISCAL QUARTER ENDED SEPTEMBER 30, 2026
ADC Therapeutics Announces New Employee Inducement Grant
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market4 days agoBinance hack may involve private key ‘misuse,’ not theft: Blockaid CEO
-
Coin Market4 days agoCanton Foundation grants RedStone 15.8M Canton Coin for pricing standard
-
Technology4 days agoMoonello Shifts Focus to AI and Software Engineering, Introduces Four Fixed-Fee Services
-
Technology4 days agoFrom Catapult to capital: NextFin Asia reaches first investment milestone with Indonesia’s Finfra
-
Technology4 days agoAppian Defense Cloud Achieves IL5 Authorization Across Department of War Operations
-
Technology4 days agoUnited Premier Soccer League Names Corgi Insurance Its Official Insurance Partner
-
Technology4 days ago
Thirty Weihai Companies Added to Shandong’s Green Factory List
-
Technology4 days agoThirty Weihai Companies Added to Shandong’s Green Factory List
